Tetrahydrocurcumin is a metabolite of curcumin (Item Nos.
81025 |
81025.1) that has diverse biological activities, including antioxidant, anti-inflammatory, anti-angiogenic, and anticancer properties.
1,2,3,4 It scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH; Item No.
14805) radicals in a cell-free assay with an EC
50 value of 16.8 μM.
1 Tetrahydrocurcumin (50 μM) inhibits LPS-induced increases in inducible nitric oxide synthase (iNOS) and COX-2 expression in RAW 264.7 cells.
2 It also inhibits LPS-induced increases in TNF-α release when used at a concentration of 100 μM and increases in nitric oxide (NO) production and IL-6 levels in a concentration-dependent manner. Tetrahydrocurcumin reduces carrageenan-induced paw edema in rats (ED
50 = 20 mg/kg).
3 It also reduces the formation of neocapillaries and decreases microvascular density as well as VEGF, VEGF receptor 2 (VEGFR2), and hypoxia-inducible factor-1α (HIF-1α) expression in a CaSki cervical cancer nude mouse xenograft model when administered at doses of 100, 300, and 500 mg/kg.
4